Tropifexor

Tropifexor

Chemical structure of Tropifexor

Tropifexor is a synthetic, non-steroidal agonist of the farnesoid X receptor (FXR), which is a nuclear receptor involved in the regulation of bile acid, lipid, and glucose metabolism. It is being investigated for its potential therapeutic effects in the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related diseases.

Mechanism of Action

Tropifexor functions by activating the farnesoid X receptor (FXR), a key regulator of bile acid homeostasis. FXR activation leads to the modulation of genes involved in bile acid synthesis, transport, and metabolism. This results in decreased bile acid levels, reduced hepatic inflammation, and improved lipid metabolism.

Clinical Development

Tropifexor is currently undergoing clinical trials to evaluate its efficacy and safety in patients with non-alcoholic steatohepatitis (NASH). NASH is a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver failure.

Pharmacokinetics

Tropifexor is administered orally and has been shown to have a favorable pharmacokinetic profile, with good bioavailability and a suitable half-life for once-daily dosing. It is metabolized primarily in the liver and excreted in the bile.

Potential Side Effects

As with any pharmacological agent, Tropifexor may have potential side effects. Commonly observed adverse effects in clinical trials include pruritus, gastrointestinal disturbances, and elevated liver enzymes. Monitoring of liver function tests is recommended during treatment.

Related Pages

• Farnesoid X receptor
• Non-alcoholic steatohepatitis
• Liver disease
• Bile acid